MX2023014407A - Molécula de unión biespecífica que se une a vegf y ang2 y uso de la misma. - Google Patents

Molécula de unión biespecífica que se une a vegf y ang2 y uso de la misma.

Info

Publication number
MX2023014407A
MX2023014407A MX2023014407A MX2023014407A MX2023014407A MX 2023014407 A MX2023014407 A MX 2023014407A MX 2023014407 A MX2023014407 A MX 2023014407A MX 2023014407 A MX2023014407 A MX 2023014407A MX 2023014407 A MX2023014407 A MX 2023014407A
Authority
MX
Mexico
Prior art keywords
vegf
ang2
binding molecule
bispecific
antibody
Prior art date
Application number
MX2023014407A
Other languages
English (en)
Spanish (es)
Inventor
Yiming Li
Siyi Hu
Hua Jing
Original Assignee
Innovent Biologics Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics Suzhou Co Ltd filed Critical Innovent Biologics Suzhou Co Ltd
Publication of MX2023014407A publication Critical patent/MX2023014407A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35Valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2023014407A 2021-06-04 2022-06-02 Molécula de unión biespecífica que se une a vegf y ang2 y uso de la misma. MX2023014407A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110623779 2021-06-04
PCT/CN2022/096848 WO2022253314A1 (zh) 2021-06-04 2022-06-02 结合VEGF和Ang2的双特异性结合分子以及其用途

Publications (1)

Publication Number Publication Date
MX2023014407A true MX2023014407A (es) 2024-04-23

Family

ID=84323888

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023014407A MX2023014407A (es) 2021-06-04 2022-06-02 Molécula de unión biespecífica que se une a vegf y ang2 y uso de la misma.

Country Status (11)

Country Link
US (1) US20240247057A1 (enExample)
EP (1) EP4349861A4 (enExample)
JP (1) JP2024520693A (enExample)
KR (1) KR20240023095A (enExample)
CN (1) CN117500828A (enExample)
AU (1) AU2022287100A1 (enExample)
CA (1) CA3221192A1 (enExample)
IL (1) IL309035A (enExample)
MX (1) MX2023014407A (enExample)
TW (1) TW202302633A (enExample)
WO (1) WO2022253314A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024002962A (es) * 2021-09-10 2024-05-17 Soter Biopharma Pte Ltd Anticuerpo anti-ang2, metodo de preparacion del mismo y aplicacion del mismo.
AR131237A1 (es) * 2022-12-01 2025-02-26 Innovent Biologics Suzhou Co Ltd Formulación que comprende una molécula de unión biespecífica que se une a vegf y a ang2 y uso de la misma
WO2025151018A1 (ko) * 2024-01-12 2025-07-17 주식회사 노벨티노빌리티 C-kit 및 vegf에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
TW202604956A (zh) * 2024-04-29 2026-02-01 大陸商深圳歐科健生物醫藥科技有限公司 Ang2/vegf 雙特異性結合分子
CN121517578A (zh) * 2024-08-13 2026-02-13 长春金赛药业有限责任公司 同时结合VEGF及Ang-2的Fc融合蛋白及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
AR080794A1 (es) * 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
LT3495387T (lt) 2012-07-13 2021-11-25 Roche Glycart Ag Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
WO2016073157A1 (en) * 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
CA2963175A1 (en) * 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag Bispecific antibodies and methods of use in ophthalmology
EP3600442A1 (en) * 2017-03-22 2020-02-05 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
US20220185875A1 (en) * 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2

Also Published As

Publication number Publication date
WO2022253314A1 (zh) 2022-12-08
EP4349861A4 (en) 2025-07-23
CN117500828A (zh) 2024-02-02
CA3221192A1 (en) 2022-12-08
IL309035A (en) 2024-02-01
JP2024520693A (ja) 2024-05-24
TW202302633A (zh) 2023-01-16
US20240247057A1 (en) 2024-07-25
EP4349861A1 (en) 2024-04-10
KR20240023095A (ko) 2024-02-20
AU2022287100A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
DOP2024000207A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
CL2022001670A1 (es) Inhibidores de proteínas kras mutantes
BR112021023457A2 (pt) Composto, uso do composto, composição, e, métodos para preparar a composição e um composto
ECSP23025065A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
CL2020001944A1 (es) Proteínas de fusión fc il-22 y métodos de uso.
CR20150625A (es) Composición que comprende anticuerpo que se fija al dominio ii de her2 y sus variantes acidas
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
PE20181805A1 (es) Composiciones y anticuerpos anti-tim-3
BRPI1008145B8 (pt) Proteína de ligação de antígeno biespecífica, método para preparar uma proteína de ligação de antígeno biespecífica, micro-organismo transgênico, composição farmacêutica e uso da proteína de ligação de antígeno biespecífica
UY30511A1 (es) Agonistas de ep2
UY35854A (es) Métodos para la conjugación de oxima con polipéptidos ceto-modificados
DOP2022000035A (es) Composiciones que comprenden tigolaner para el control de parásitos
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
CL2023003695A1 (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, métodos de uso
MX2021011976A (es) Composiciones de control de artropodos.
BR112017016636A2 (pt) formulação líquida estável para anticorpos monoclonais
CO6731074A2 (es) Composición vacunal para el control de las infestaciones por ectoparásitos
MX2020008125A (es) Composiciones que comprenden berberina.
MX2020006105A (es) Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica.
CL2022001035A1 (es) Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas
AR106981A1 (es) Una composición antimicrobiana
MX2023001160A (es) Composicion farmaceutica del anticuerpo anti-pd-1 y uso del mismo.
AR117343A1 (es) AGENTES DE UNIÓN REVERSIBLE PARA ANTICUERPOS ANTI-FACTOR XI / XIa Y USOS DE LOS MISMOS
CL2023000491A1 (es) Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020).
CL2025000292A1 (es) Anticuerpos tmem219 y usos terapéuticos de los mismos